SHENZHEN, China, March 21, 2011 /PRNewswire-Asia-FirstCall/ -- Tongjitang Chinese Medicines Company (the "Company" or "Tongjitang") (NYSE: TCM), a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced that it plans to release its fourth quarter and full year 2010 financial results after the market close on March 25, 2011.
Tongjitang's management team will hold a conference call on Monday, March 28, 2011, at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Beijing/Hong Kong time) following the announcement. Listeners may access the call by dialing the following numbers:United States toll free:1-877-941-2321Hong Kong toll free:
800-908-530China toll free:
1-480-629-9714Listeners may access the replay from approximately two hours after the call ends through April 4, 2011 by dialing the following numbers:
United States toll free:1-877-870-5176International:
4426889An audio webcast of the call will also be available through the Company's website at www.tongjitang.com.
About Tongjitang Chinese Medicines CompanyTongjitang Chinese Medicines Company, through its operating subsidiaries Guizhou Tongjitang Pharmaceutical Co., Ltd., Guizhou Long-Life Pharmaceutical Company Limited, Qinghai Pulante Pharmaceutical Co., Ltd. and Anhui Jingfang Pharmaceutical Co., Ltd., is a vertically integrated specialty pharmaceutical company focused on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China. Tongjitang's principal executive offices are located in Shenzhen, China.
Tongjitang's flagship product, Xianling Gubao, is the leading traditional Chinese medicine for the treatment of osteoporosis in China as measured by sales in Renminbi. In addition to Xianling Gubao, the Company manufactures and markets 35 other modernized traditional Chinese medicine products and 36 western medicines. Please visit www.tongjitang.com for more information.
CONTACTICR, LLCAshley M. Ammon 203-682-8200 (Investor Relations)
|SOURCE Tongjitang Chinese Medicines Company|
Copyright©2010 PR Newswire.
All rights reserved